Renalytix Plc (LON:RENX – Get Free Report) shares rose 18.5% on Friday . The stock traded as high as GBX 3.90 and last traded at GBX 3.85. Approximately 2,615,687 shares traded hands during mid-day trading, an increase of 197% from the average session volume of 881,370 shares. The stock had previously closed at GBX 3.25.
Renalytix Stock Performance
The stock has a 50-day simple moving average of GBX 2.40 and a 200-day simple moving average of GBX 2.84. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42. The stock has a market cap of £16.83 million, a PE ratio of -0.96 and a beta of 1.81.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Further Reading
- Five stocks we like better than Renalytix
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
